Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study of baricit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arthritis Res Ther
Autori principali: Emery, Paul, Durez, Patrick, Hueber, Axel J., de la Torre, Inmaculada, Larsson, Esbjörn, Holzkämper, Thorsten, Tanaka, Yoshiya
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784289/
https://ncbi.nlm.nih.gov/pubmed/33397481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02379-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi